BioNTech SE
Market Data Current As Of: September 12, 2026
Related Competitor Intelligence
Compare market positioning with top industry peers
Explore BioNTech
Core profile pages, annual revenue records, and related research hubs for this company.
BioNTech SE
Compare market positioning with top industry peers
Explore BioNTech
Core profile pages, annual revenue records, and related research hubs for this company.
Financial Performance
Revenue
$3.2B
Market Cap
$21.5B
Employees
6,400
BioNTech is navigating a structural transition following the end of the global COVID-19 pandemic. Under CEO Uğur Şahin, the German biotechnology company saw its revenues normalize to exactly $4.1 billion in 2026, maintaining a $21.5 billion market cap with a specialized workforce of exactly 6400 employees. The financial narrative is defined by capital redeployment; BioNTech is utilizing the multi-billion-dollar cash stockpile it accumulated during the pandemic to pivot its foundational mRNA technology platform toward individualized cancer immunotherapies. The company is funding concurrent clinical trials, attempting to bring its first oncology products to market before the end of the decade.
Revenue Trend Analysis
YoY Change
+4.3%
3-Year CAGR
-44.8%
Peak Year
2022
Trend
Declining Trend
BioNTech SE has reported revenue across 4 fiscal years, compounding at -44.8% annually over 3 years. The most recent year saw a 4.3% increase versus the prior year. Revenue peaked in 2022 at $18.9B. Out of 3 reported periods, 1 showed growth and 2 showed a decline.
| Fiscal Year | Revenue | YoY Change |
|---|---|---|
| FY2025 | $3.2B | +4.3% |
| FY2024 | $3.0B | -26.9% |
| FY2023 | $4.2B | -78.0% |
| FY2022 | $18.9B | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
BioNTech SE reported approximately $4.1B in fiscal year 2025 with a team of 6,400 employees worldwide.
BioNTech SE strategically balances reinvestment into core R&D with operational cost discipline, focusing on workflow automation to expand operating margins in 2026.
Financial performance in Biotechnology / Immunotherapy is driven by steady cash generation and pricing power, enabling BioNTech SE to reinvest in high-return strategic initiatives.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "BioNTech SE Revenue & Financials." CorpDigest, https://corpdigest.com/company/biontech/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>BioNTech SE reported $3B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/biontech/financials" target="_blank" rel="noopener">CorpDigest — BioNTech SE financials</a></div>